Cellular Biomedicine Group to Release CAR-T for Non-Small Cell Lung Cancer Phase I Clinical Trial Data at 2015 European Cance...
September 21 2015 - 8:46PM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective stem cell therapies for degenerative diseases and
immunotherapies for cancer, today announced a scheduled poster
presentation during the 2015 European Cancer Congress (ECCO) annual
meeting to be held in Vienna, Austria from September 25-29, 2015.
The presentation will detail PLAGH/CBMG's Phase I clinical trial
data using Chimeric Antigen Receptor-Modified T-Cells (CAR-T)
targeting HER-1 for the treatment of patients with HER-1 expressing
advanced relapsed/refractory Non-Small Cell Lung Cancer (NSCLC).
The CAR-T trial was designed and conducted by Chinese PLA General
Hospital ("PLAGH", Beijing, also known as "301 Hospital"), led by
Principal Investigator Wei Dong Han, MD, PhD, head of PLAGH's
cancer immunotherapy department. Dr. Han and his research team have
authored several CAR-T publications, including "Tolerance and
Efficacy of Autologous or Donor-derived T-Cells Expressing CD19
Chimeric Antigen Receptors in Adult B-ALL with Extramedullary
Leukemia" and "Effective Response and Delayed Toxicities of
Refractory Advanced Diffused Large B-cell Lymphoma Treated by
CD20-directed Chimeric Antigen Receptor-modified T-cells".
(OncoImmunology (Impact Factor: 6.28). 03/2015; DOI:
10.1080/2162402X.2015.1027469 and Clin Immunol. 2014
Dec;155(2):160-75. doi: 10.1016/j.clim.2014.10.002) The Company
previously announced positive clinical data from its Phase I
clinical trials for CD19, CD20 and CD30 constructs targeting
late-stage blood cancers.
Title: Chimeric Antigen Receptor-Modified
T-Cells for the immunotherapy of Patients with HER-1 Expressing
Advanced Relapsed/Refractory Non-Small Cell Lung Cancer
Poster Session: Immunotherapy of Cancer, September
26 2015 from 16:45 to 18:45 (CEST) Abstract
Number: 516 Poster Number:
P250 Location: Messe Wien Exhibition &
Congress Centre, Hall C Presenter: Wei Dong
Han, MD, PhD, Chinese PLA General Hospital
Company management will participate in the meeting and be
available for discussions. Full detail of the presented data will
be available on the Company website following the presentation.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative and cancerous
diseases. Our developmental stem cell and Immuno-Oncology
projects are the result of research and development by scientists
and doctors from China and the United States. Our
flagship GMP facility in China, consisting of six independent cell
production lines, is designed, certified and managed according to
U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy,
including the devaluation of the RMB by China in August 2015 and
other risks detailed from time to time in CBMG's reports filed with
the Securities and Exchange Commission, quarterly reports on form
10-Q, current reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024